- Home
- SRG vs DMAC Comparison
SRG vs DMAC Comparison
Compare SRG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- DMAC
- Stock Information
- Founded
- SRG 2014
- DMAC 2000
- Country
- SRG United States
- DMAC United States
- Employees
- SRG N/A
- DMAC N/A
- Industry
- SRG Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- DMAC Health Care
- Exchange
- SRG Nasdaq
- DMAC Nasdaq
- Market Cap
- SRG 163.3M
- DMAC 158.1M
- IPO Year
- SRG 2015
- DMAC N/A
- Fundamental
- Price
- SRG $2.82
- DMAC $4.11
- Analyst Decision
- SRG
- DMAC Strong Buy
- Analyst Count
- SRG 0
- DMAC 2
- Target Price
- SRG N/A
- DMAC $8.00
- AVG Volume (30 Days)
- SRG 122.6K
- DMAC 102.4K
- Earning Date
- SRG 05-15-2025
- DMAC 05-13-2025
- Dividend Yield
- SRG N/A
- DMAC N/A
- EPS Growth
- SRG N/A
- DMAC N/A
- EPS
- SRG N/A
- DMAC N/A
- Revenue
- SRG N/A
- DMAC N/A
- Revenue This Year
- SRG N/A
- DMAC N/A
- Revenue Next Year
- SRG N/A
- DMAC N/A
- P/E Ratio
- SRG N/A
- DMAC N/A
- Revenue Growth
- SRG N/A
- DMAC N/A
- 52 Week Low
- SRG $2.43
- DMAC $2.14
- 52 Week High
- SRG $5.52
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SRG 42.26
- DMAC 50.90
- Support Level
- SRG $2.81
- DMAC $3.92
- Resistance Level
- SRG $2.99
- DMAC $4.33
- Average True Range (ATR)
- SRG 0.09
- DMAC 0.29
- MACD
- SRG -0.00
- DMAC 0.02
- Stochastic Oscillator
- SRG 11.54
- DMAC 56.79
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.